DEVELOPMENT OF PYRAZINE-CONTAINING HYBRIDS WITH ANTI-INFLAMMATORY POTENTIAL

The development of pyrazine-containing hybrids with potential anti-inflammatory activity represents an exciting frontier in pharmaceutical research, particularly for the design of novel therapeutic agents for the treatment of chronic inflammatory diseases. Pyrazines, a class of nitrogen-containing heterocycles, have gained considerable attention in medicinal chemistry due to their diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. This research explores the design, synthesis, and biological evaluation of pyrazine-based hybrid compounds that combine the core structure of pyrazine with other bioactive pharmacophores to enhance their anti-inflammatory efficacy. In the past decade, the global burden of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis has prompted the search for more effective and selective anti-inflammatory drugs. Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) often come with significant side effects, including gastrointestinal toxicity and renal impairment, which limit their long-term use. Therefore, there is an urgent need for the discovery of novel anti-inflammatory agents that are not only potent but also exhibit fewer adverse effects. Pyrazine-containing hybrids have shown promise in this regard due to their ability to modulate key inflammatory pathways, including the inhibition of cyclooxygenase (COX) enzymes, suppression of pro-inflammatory cytokines, and reduction of oxidative stress. The synthesis of pyrazine-containing hybrids typically involves the covalent attachment of pyrazine moieties to other bioactive scaffold structures through various chemical linkers. The choice of the second pharmacophore is critical, as it can enhance the overall anti-inflammatory profile by targeting specific molecular pathways involved in inflammation. This study focuses on the synthesis of a series of pyrazine-based hybrids with different structural modifications and evaluates their anti-inflammatory potential through in vitro and in vivo assays. The compounds are tested for their ability to inhibit the production of pro-inflammatory mediators such as prostaglandins, cytokines, and nitric oxide, while also assessing their toxicity and selectivity towards inflammation pathways.